logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Terms of Reference for Scientific Advisory Panel on Opioid Use and Contraindications

February 28, 2017
-
Market Access News
-
Posted by MORSE Team - < 1 min read.

Health Canada Update

 

On February 24, 2017, Health Canada issued the Terms of Reference for the Scientific Advisory Panel on Opioid Use and Contraindications (SAP-OUC). According to Health Canada’s website, the SAP-OUC will “examine whether contraindications currently included in Canadian labelling of opioids are sufficient or should be modified, and whether additional contraindications should be added. While the Panel provides Health Canada with advice and recommendations, the decision-making responsibility remains with Health Canada.” Please select the URL below to access additional information related to the SAP-OUC’s:

  • Mandate
  • Reporting Structure
  • Membership/Participation/Qualifications
  • Roles and Responsibilities
  • Management and Administration
  • References

 

For more information visit the (SAP-OUC) website

 

To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.

 

Share
Tags
Health Canada
Opioids
Product labelling
SAP-OUC
← PREVIOUS POST
Canada Attempts Biosimilar Balancing Act
NEXT POST →
BC Pharmacare Newsletter- February 2017

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2021 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Terms of Reference for Scientific Advisory Panel on Opioid Use and Contraindications
Private
Public
Private

INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB

Public
INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB
Public
Private
Public
INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB
Private

INESSS
CADTH

HTA

pCPA

Public Payers

Health Canada

Patients

Private Payers

PMPRB